Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L51374] It binds to a different epitope compared [tralokinumab]. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  2. Drug

    Polythiazide

    go.drugbank.com/drugs/DB01324
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

  3. Drug

    Sorbitol

    go.drugbank.com/drugs/DB01638
    ApprovedInvestigational

    It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    It has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.

    Categories: Complex Mixtures
  5. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.

  6. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  7. Drug

    Hydromorphone

    go.drugbank.com/drugs/DB00327
    ApprovedIllicitInvestigational

    Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]

  8. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).

  9. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]

  10. Drug

    Temazepam

    go.drugbank.com/drugs/DB00231
    Approved

    In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to … synthesis of temazepam was established by 1965 [A175333], mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on

    Products: Gen-temazepam 15mg, Gen-temazepam 30mg